Investor Insight
BriaCell Therapeutics is pioneering a new class of off-the-shelf personalized immunotherapies, exploring the potential to double overall survival in advanced breast cancer.
Overview
BriaCell Therapeutics (TSX:BCT,NASDAQ:BCTX) is a clinical-stage immuno-oncology company dedicated to transforming cancer care through the development of new classes of targeted immunotherapies. Its lead drug candidate is the Bria-IMT Cell Therapy, an off-the-shelf therapy designed to activate a patient’s immune system to target cancer cells without harming other cells. Bria-IMT™ is currently the subject of a pivotal Phase 3 study, under Fast Track designation, aimed at securing full approval from the US Food and Drug Administration (FDA).
The company is also advancing the Bria-OTS™ and Bria-OTS+™, a personalized off-the-shelf platform that aims to provide an innovative way to treat breast cancer and eventually expand to prostate and lung cancer and melanoma therapies.
BriaCell’s strategy is built on clinical validation and capital efficiency, with its seasoned team of scientists and clinicians having a combined record of 20 drug and device approvals.
Company Highlights
- Proven Survival Data: Clinical data have demonstrated an approximate doubling of overall survival compared to physician-placed chemotherapy.
- Personalized Immunotherapy: Its Bria-OTS™ platform uses a simple saliva test to provide HLA-matched therapy to over 99 percent of patients at a reasonable cost.
- Experienced Management: Leadership boasts a track record of 20 successful drug or device approvals, significantly de-risking the clinical and regulatory pathway.
- Expert Validation and Support: Recognized by Nature Medicine as a top transformative clinical trial of 2026 and supported by a grant from the National Cancer Institute.
Key Technologies
Bria-IMT™ Cell Therapy
Bria-IMT™ is a cell-based immunotherapy designed to stimulate the immune system to enhance targeted killing of cancer cells. The company’s lead drug candidate, Bria-IMT is a patented, off-the-shelf and targeted immunotherapy that is currently the subject of a pivotal Phase 3 study.
The technology has shown the ability to double overall survival rates in patients with metastatic breast cancer in its clinical trials compared to traditional chemotherapy. Data also suggest remarkable clinical efficacy in patients with central nervous system metastases, alongside excellent tolerability with no dose-limiting toxicities.
Bria-IMT™ has been awarded fast-track designation by the FDA. The company is advancing to detect a 40 percent reduction in mortality using the technology, as positive results could lead to full approval of Bria-IMT.
Bria-OTS™ and Bria-OTS+™ Platforms
Building on Bria-IMT™, Bria-OTS™ was designed to be a more advanced "off-the-shelf” personalized immunotherapy. By using a simple saliva test, clinicians can match a patient to one of four independent cell lines that cover over 99 percent of the population's human leukocyte antigen (HLA) types. Early results with this platform indicate clinical anti-cancer activity as single agent therapy.
The company is developing Bria-OTS+™, an advanced version of Bria-OTS, engineered for greater potency. BriaCell has received clearance from the FDA for its investigational new drug application for Bria-BRES+™, the Phase 1/2 Study of Bria-OTS+™ for metastatic breast cancer. The platform also plans to expand into prostate cancer (Bria-PROS+™), lung cancer (Bria-LUNG+™) and melanoma (Bria-MEL+™).
Following this, BriaCell expects trial initiation, safety data and potential efficacy signals to further validate the platform as it moves forward.
Management Team
Dr. William V. Williams – President & CEO
With over 35 years of experience, Dr. Williams has spearheaded numerous successful clinical programs. He previously served as the Head of Rheumatology Research at the University of Pennsylvania, where he led a major research program in receptor biology and brought novel DNA vaccines to the clinic for the treatment of cutaneous T cell lymphoma. As VP of Exploratory Development at Incyte Corporation from 2005 to 2016, he facilitated the entry of over 20 compounds, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
Dr. Giuseppe Del Priore – Chief Medical Officer
Dr. Del Priore brings extensive experience in gynecologic oncology and clinical trial management. Recognized as a Key Opinion Leader (KOL) in oncology with several patents to his name, he is also an author and was listed among the “Best Doctors” by the U.S. News & World Report. He oversees the clinical development of BriaCell’s lead candidates and ensures the rigorous execution of the pivotal Phase 3 program.
Miguel A. Lopez-Lago – Chief Scientific Officer
Dr. Lopez-Lago is a veteran cancer scientist with over 20 years of experience at Memorial Sloan-Kettering Cancer Center (MSKCC), specializing in tumor biology and the mechanisms of metastasis. His recent research focuses on the tumor immune-microenvironment and the development of advanced immunotherapies, including CAR T cell technologies for thoracic cancers.
